VIYASH · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 50/100 — Quality 53 · Valuation 17 · Momentum 100
| Share price | ₹264.55 |
| Market cap | ₹12,125 Cr |
| P/E ratio | 69.5 |
| P/B ratio | 4.1 |
| ROCE | 11.4% |
| Book value | ₹67.04 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,420 Cr | ₹225 Cr | 19.0% |
| 2025 | ₹1,551 Cr | ₹32 Cr | 10.0% |
| 2024 | ₹1,370 Cr | ₹-30 Cr | 4.0% |
| 2023 | ₹1,421 Cr | ₹-122 Cr | 1.0% |
| 2022 | ₹1,413 Cr | ₹45 Cr | 8.0% |
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientifi